Back to Search
Start Over
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
- Source :
-
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2017 Sep; Vol. 23 (9), pp. 627-633. Date of Electronic Publication: 2017 Jul 11. - Publication Year :
- 2017
-
Abstract
- The duration of fever and symptoms after laninamivir octanoate hydrate (laninamivir) inhalation were investigated in the Japanese 2015/16 influenza season, and the results were compared with those of the 2011/12 to 2014/15 seasons. A total of 1068 patients were evaluated for the duration of fever and symptoms in the five studied seasons. The influenza types/subtypes were 125 A(H1N1)pdm09 (62.2%), 17 A(H3N2) (8.5%), and 59 B (29.4%) in the 2015/16 season. The median durations of fever were 40.0, 41.0, and 47.0 h, and the median durations of symptoms were 87.0, 76.0, and 93.0 h for A(H1N1)pdm09, A(H3N2), and B, respectively, with no significant difference. The median durations of fever were 52.0 and 46.0 h and the median durations of symptoms 93.0 and 88.0 h for the Victoria and Yamagata B lineages, respectively, with no significant difference. Fever resolution after laninamivir inhalation by the A(H1N1)pdm09 patients was similar in the 2013/14 and 2015/16 seasons. Fever resolution after laninamivir inhalation was similar in all comparisons of the 2011/12 to 2015/16 seasons for both A(H3N2) and B, with no significant difference among the five seasons. Over the seasons tested, eight adverse drug reactions (ADRs) were reported for 1128 patients. The most frequent ADR was diarrhea, and all ADRs were resolved and not serious. These results indicate the continuing clinical effectiveness of laninamivir against influenza A(H1N1)pdm09, A(H3N2), and B, with no safety issues.<br /> (Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Administration, Inhalation
Adolescent
Adult
Aged
Antiviral Agents administration & dosage
Child
Enzyme Inhibitors adverse effects
Enzyme Inhibitors therapeutic use
Female
Fever drug therapy
Guanidines
Humans
Influenza, Human physiopathology
Influenza, Human virology
Male
Middle Aged
Neuraminidase antagonists & inhibitors
Pregnancy
Product Surveillance, Postmarketing
Pyrans
Sialic Acids
Treatment Outcome
Young Adult
Zanamivir administration & dosage
Zanamivir therapeutic use
Antiviral Agents therapeutic use
Influenza, Human drug therapy
Zanamivir analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7780
- Volume :
- 23
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 28709902
- Full Text :
- https://doi.org/10.1016/j.jiac.2017.06.008